Tonghua Dongbao Pharmaceutical Co., Ltd.

SHSE:600867 Stock Report

Market Cap: CN¥15.2b

Tonghua Dongbao Pharmaceutical Future Growth

Future criteria checks 4/6

Tonghua Dongbao Pharmaceutical is forecast to grow earnings and revenue by 61.7% and 17.4% per annum respectively. EPS is expected to grow by 65% per annum. Return on equity is forecast to be 11.9% in 3 years.

Key information

61.7%

Earnings growth rate

65.01%

EPS growth rate

Pharmaceuticals earnings growth14.4%
Revenue growth rate17.4%
Future return on equity11.95%
Analyst coverage

Low

Last updated20 May 2025

Recent future growth updates

Recent updates

Is Tonghua Dongbao Pharmaceutical (SHSE:600867) Using Too Much Debt?

Feb 21
Is Tonghua Dongbao Pharmaceutical (SHSE:600867) Using Too Much Debt?

Investors Appear Satisfied With Tonghua Dongbao Pharmaceutical Co., Ltd.'s (SHSE:600867) Prospects

Jan 02
Investors Appear Satisfied With Tonghua Dongbao Pharmaceutical Co., Ltd.'s (SHSE:600867) Prospects

Tonghua Dongbao Pharmaceutical (SHSE:600867) Has A Pretty Healthy Balance Sheet

Oct 22
Tonghua Dongbao Pharmaceutical (SHSE:600867) Has A Pretty Healthy Balance Sheet

Tonghua Dongbao Pharmaceutical Co., Ltd.'s (SHSE:600867) Earnings Haven't Escaped The Attention Of Investors

Sep 30
Tonghua Dongbao Pharmaceutical Co., Ltd.'s (SHSE:600867) Earnings Haven't Escaped The Attention Of Investors

Some May Be Optimistic About Tonghua Dongbao Pharmaceutical's (SHSE:600867) Earnings

Sep 06
Some May Be Optimistic About Tonghua Dongbao Pharmaceutical's (SHSE:600867) Earnings

Tonghua Dongbao Pharmaceutical Co., Ltd. (SHSE:600867) Analysts Just Slashed This Year's Estimates

Sep 05
Tonghua Dongbao Pharmaceutical Co., Ltd. (SHSE:600867) Analysts Just Slashed This Year's Estimates

Calculating The Intrinsic Value Of Tonghua Dongbao Pharmaceutical Co., Ltd. (SHSE:600867)

Aug 22
Calculating The Intrinsic Value Of Tonghua Dongbao Pharmaceutical Co., Ltd. (SHSE:600867)

Tonghua Dongbao Pharmaceutical (SHSE:600867) Has A Rock Solid Balance Sheet

Jun 19
Tonghua Dongbao Pharmaceutical (SHSE:600867) Has A Rock Solid Balance Sheet

Improved Earnings Required Before Tonghua Dongbao Pharmaceutical Co., Ltd. (SHSE:600867) Shares Find Their Feet

May 23
Improved Earnings Required Before Tonghua Dongbao Pharmaceutical Co., Ltd. (SHSE:600867) Shares Find Their Feet

Earnings and Revenue Growth Forecasts

SHSE:600867 - Analysts future estimates and past financials data (CNY Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20273,4328084561,1733
12/31/20263,1538253201,0035
12/31/20252,7505741058165
3/31/20252,070-148-156405N/A
12/31/20242,010-43-109460N/A
9/30/20242,43234175614N/A
6/30/20242,449453227667N/A
3/31/20243,0011,132524858N/A
12/31/20233,0751,168513862N/A
9/30/20232,771939130528N/A
6/30/20232,757884213611N/A
3/31/20232,5561,001213666N/A
12/31/20222,7781,582370863N/A
9/30/20222,9121,6435651,185N/A
6/30/20222,9931,8204051,160N/A
3/31/20223,3321,8034761,163N/A
12/31/20213,2681,3085801,180N/A
9/30/20213,1621,2426541,147N/A
6/30/20213,0791,0608491,188N/A
3/31/20212,9969898541,206N/A
12/31/20202,8929307131,192N/A
9/30/20202,9068796581,054N/A
6/30/20202,8178207941,174N/A
3/31/20202,7818158561,119N/A
12/31/20192,7778118591,152N/A
9/30/20192,7418397871,109N/A
6/30/20192,6648344771,001N/A
3/31/20192,6888381391,099N/A
12/31/20182,693839N/A877N/A
9/30/20182,701876N/A938N/A
6/30/20182,827963N/A954N/A
3/31/20182,699900N/A898N/A
12/31/20172,545837N/A961N/A
9/30/20172,414789N/A900N/A
6/30/20172,332736N/A818N/A
3/31/20172,154690N/A840N/A
12/31/20162,040641N/A726N/A
9/30/20161,909604N/A687N/A
6/30/20161,779546N/A577N/A
3/31/20161,722533N/A359N/A
12/31/20151,669493N/A295N/A
9/30/20151,661450N/A248N/A
6/30/20151,576393N/A105N/A
3/31/20151,521321N/A158N/A
12/31/20141,451280N/A206N/A
9/30/20141,369215N/A142N/A
6/30/20141,308216N/A285N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 600867 is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.7%).

Earnings vs Market: 600867 is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: 600867 is expected to become profitable in the next 3 years.

Revenue vs Market: 600867's revenue (17.4% per year) is forecast to grow faster than the CN market (12.4% per year).

High Growth Revenue: 600867's revenue (17.4% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: 600867's Return on Equity is forecast to be low in 3 years time (11.9%).

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/06/03 12:29
End of Day Share Price 2025/06/03 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Tonghua Dongbao Pharmaceutical Co., Ltd. is covered by 24 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Kan LiChasing Securities
Yanyin ZhuChina International Capital Corporation Limited
Bing ZhaoChina Renaissance Securities